de Vries Jessica, Dejongste Mike J L, Durenkamp Ans, Zijlstra Felix, Staal Michiel J
Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Eur J Pain. 2007 Apr;11(3):360-5. doi: 10.1016/j.ejpain.2006.04.002. Epub 2006 Jun 9.
To assess the long-term efficacy of neurostimulation for treating refractory angina pectoris-like chest pain, we followed patients, treated with either transcutaneous electrical nerve stimulation (TENS) or spinal cord stimulation (SCS).
Neurostimulation was judged successful and subsequently continued when initial pain was reduced at least 50%. All patients started with TENS, but if skin irritation occurred during TENS, a SCS system was implanted. The quality of life was measured at baseline and follow-up with the Seattle Angina Questionnaire. Additional information was gathered concerning anti-anginal medication, complaints, and physical condition.
Of 36 patients treated successfully with neurostimulation, we identified 24 patients after a mean (SD) follow-up period of 5.08 (3.86) years; 12 patients dropped out of the study. In 13 of the remaining 24 patients, TENS induced skin irritation. Eight of these 13 patients received successful SCS, while five refused implantation. In the 24 patients, a mean pain reduction of 57% was achieved in conjunction with an increased exercise capacity of 30% and walking distance increased from 0.73 (0.83) to 1.62 (1.62) (p=0.018). Within the Seattle Angina Questionnaire the domain 'disease perception' improved from 38.89 (16.61) to 49.31 (21.83) (p=0.004), the domain 'physical limitation' improved from 29.89 (15.10) to 40.97 (22.63) (p=0.001) and 'anginal frequency' improved from 41.67 (24.08) to 55.00 (23.03) (p=0.005). In addition, nitroglycerin consumption was reduced from 7.85 (8.49) to 1.98 (2.19) (p=0.001).
Neurostimulation techniques should thus be of widespread value for treating angina pectoris-like chest pain in patients who are refractory to medication.
为评估神经刺激治疗难治性心绞痛样胸痛的长期疗效,我们对接受经皮电神经刺激(TENS)或脊髓刺激(SCS)治疗的患者进行了随访。
当初始疼痛减轻至少50%时,判定神经刺激成功并随后继续治疗。所有患者均从TENS开始治疗,但如果在TENS治疗期间出现皮肤刺激,则植入SCS系统。在基线和随访时使用西雅图心绞痛问卷测量生活质量。收集有关抗心绞痛药物、症状和身体状况的其他信息。
在36例接受神经刺激成功治疗的患者中,我们在平均(标准差)5.08(3.86)年的随访期后确定了24例患者;12例患者退出研究。在其余24例患者中的13例中,TENS引起了皮肤刺激。这13例患者中的8例接受了成功的SCS治疗,而5例拒绝植入。在这24例患者中,平均疼痛减轻了57%,同时运动能力提高了30%,步行距离从0.73(0.83)增加到1.62(1.62)(p=0.018)。在西雅图心绞痛问卷中,“疾病认知”领域从38.89(16.61)提高到49.31(21.83)(p=0.004),“身体限制”领域从29.89(15.10)提高到40.97(22.63)(p=0.001),“心绞痛发作频率”从41.67(24.08)提高到55.00(23.03)(p=0.005)。此外,硝酸甘油消耗量从7.85(8.49)减少到1.98(2.19)(p=0.001)。
因此,神经刺激技术对于治疗对药物治疗无效的心绞痛样胸痛应具有广泛的价值。